BCL2 and neoplasm: To overcome the drawback of drug resistance, the co-administration of ABT199, a Bcl-2 inhibitor, was simultaneously released from the nanofibers, which deactivated the Bcl-2 protein and thereby enhanced the apoptosis of drug-resistant tumor cells.